The FDA has adjusted the label of Johnson & Johnson and Legend Biotech’s Carvykti, warning patients and doctors that use of ...
The U.S. Food and Drug Administration approved on Friday labeling changes for the blood cancer therapy of Johnson & Johnson ...
The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to ...
The FDA adds a new boxed warning for immune effector cell-associated enterocolitis with Carvykti, but says the overall ...
Legend Biotech Corporation (NASDAQ:LEGN) is one of the best healthcare stocks with the highest upside. J.P. Morgan analyst ...
The US Food and Drug Administration (FDA) on Friday revealed it has received reports of immune effector cell-associated ...
The much-anticipated CAR-T showdown between Bristol Myers Squibb and the alliance of Johnson & Johnson and Legend Biotech in the early treatment of multiple myeloma has arrived sooner than ...
CARTITUDE-4 analysis shows compelling overall survival and progression-free benefits in standard and high-risk subgroups across prior lines of treatment In a subset of 12 patients who underwent serial ...
Zacks.com on MSN
Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings?
JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.
Expanded indication for this one-time infusion will provide more patients with a potential period away from their multiple myeloma treatment as early as first relapse Approval is based on results from ...
SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat ...
The U.S. Food and Drug Administration (FDA) has updated the safety labeling for Carvykti, the multiple myeloma therapy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback